Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Conditions

• Leiomyosarcoma
• Liposarcoma
• Retroperitoneal Sarcoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Surgery — PROCEDURE
  Large en-bloc curative-intent surgery
• Preoperative chemotherapy — DRUG
  * High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks * LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same.

Study Details

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.

Key Dates

Start date

Jan 20, 2021

Status verified

May 2026

Primary completion

Apr 21, 2027

Completion

Apr 21, 2028

Study Design

Enrollment

250 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Other: Standard arm
  Surgery alone
• Experimental: Experimental arm
  Preoperative chemotherapy and surgery

Primary Outcome Measure

Disease free survival [ Time Frame: 7 years from first patient in ]

Central Contacts

• EORTC HQ
  +3227741611
  [email protected]

Locations (109)

Find similar trials in Birmingham, AL

Related Studies

• Proton or Photon RT for Retroperitoneal Sarcomas
  PHASE1/PHASE2 · Recruiting · Massachusetts General Hospital · Chicago, Illinois
• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
  Recruiting · Sanford Health · Sioux Falls, South Dakota
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
  PHASE3 · Recruiting · Advenchen Laboratories, LLC · Phoenix, Arizona
• REtroperitoneal SArcoma Registry: an International Prospective Initiative
  Recruiting · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Los Angeles, California